CoChat

Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Purpose To assess and compare the therapeutic efficacy of Liraglutide, Tirzepatide, and Retatrutide in treating diabetic kidney disease (DKD) in db/db mice. Methods Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks. Subsequently, we assessed the effectiveness of these three drugs in controlling blood glucose levels, reducing weight, and improving serum biochemical indicators and DKD. Additionally, we measured and compared the renal inflammation and fibrosis indexes. Meanwhile, the content of intestinal metabolite butyrate was compared to reflect the regulatory effects of these three drugs on gut microbiota. Results Retatrutide demonstrated superior effectiveness in reducing weight and improving renal function in db/db mice compared to Liraglutide and Tirzepatide. Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice. Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs. Unfortunately, despite its ability to lower blood glucose levels, Retatrutide did not outperform the other two drugs…

Overview

Integrity signals

Registry

Crossref · 10.1007/s12020-024-03998-8

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 36 references

Cited by

See all 21

Metadata

Authors
Ma, J., Hu, X., Zhang, W., Tao, M., Wang, M., & Lu, W.
Affiliations
Huaian First People’s Hospital (CN)
Corresponding author
  • Wang, Min
  • Lu, Weiping
Venue
Endocrine
Published
2024-08-30
Volume
87
Issue
1
Pages
159-169
ISSN
  • 0969-711X (ISSN-L)
  • 1559-0100
OpenAlex
W4402061935
Cited by
21
References
36
Citations by year
2026: 10 · 2025: 11
FWCI
6.01
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Endocrine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Development Fund of the Affiliated Hospital of Xuzhou Medical University (No. XYFY2021031.)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
diabetic nephropathy, liraglutide, tirzepatide, retatrutide, db/db mice, renal fibrosis, renal inflammation, butyrate, gut microbiota, intestinal metabolites, glycemic control, weight loss, lipid metabolism, inflammatory cytokines, NLRP3 inflammasome, caspase-1, fibronectin, type 2 diabetes
MeSH terms
Gastrointestinal Microbiome, Liraglutide, Tirzepatide, Animals, Blood Glucose, Diabetes Mellitus, Experimental, Diabetic Nephropathies, Fatty Acids, Hypoglycemic Agents, Kidney, Male, Mice, Inbred C57BL, Peptides, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. https://app.cochat.ai/papers/10.1007/s12020-024-03998-8
The paper
Ma, J., Hu, X., Zhang, W., Tao, M., Wang, M., & Lu, W. (2024). Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. https://doi.org/10.1007/s12020-024-03998-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.